Amirreza Ehsani - Department of Surgery, Iran University of Medical Sciences (IUMS), Tehran, Iran
Nahid Nafissi - Department of Surgery, Iran University of Medical Sciences (IUMS), Tehran, Iran
Mohammadamin Joulani - Student Research Committee, Iran University of Medical Sciences (IUMS), Tehran, Iran

Background: Nowadays breast cancer (BC) is the most common cancer in women. More than ۱.۵ million cases are detected yearly. Survival of patients is dependent on several factors. Metastasis and cancer recurrence of different types and in different locations have various outcome.Methods: This is a retrospective cohort study to describe survival of patients after diagnosis of breast cancer based on receptor subtypes and sites of metastasis among Iranian population. A total number of ۲۰۵۱ females with breast cancer were evaluated and among these, ۱۳۸ patients with recurrent BC were investigated.Results: The ۱-year survival of local, bone, visceral and brain metastasis were ۶۴.۹۹%, ۶۳%, ۳۲.۸۳%, and ۲۱.۵۷%, respectively. Based on sites of metastasis, bone and local metastasis showed the best survival while brain and visceral metastasis had the worst survival and prognosis.Conclusion: Our study showed that HER۲ enriched positive BCs had the worst survival, this may be due to Trastuzumab uncovered insurance till ۱۰ years ago in our country. Also, drugs related to luminal A and B which are used to improve their survival and hormonal therapy could be associated with their better prognosis in comparison to triple negative receptor subtype. But this study showed that triple negative BC had better survival.

Breast Cancer, recurrence, metastasis, survival